On Monday, Nektar Therapeutics (NASDAQ: NKTR) was 5.12% up from the session before settling in for the closing price of $56.68. A 52-week range for NKTR has been $0.43 – $66.92.
During the last 5-year period, the sales growth of Healthcare Sector giant was 25.49%. When this article was written, the company’s average yearly earnings per share was at -14.79%. With a float of $19.90 million, this company’s outstanding shares have now reached $20.34 million.
Nektar Therapeutics (NKTR) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Nektar Therapeutics stocks. The insider ownership of Nektar Therapeutics is 2.18%, while institutional ownership is 70.34%. The most recent insider transaction that took place on Sep 09 ’25, was worth 311,214. In this transaction President & CEO of this company sold 6,666 shares at a rate of $46.69, taking the stock ownership to the 49,342 shares. Before that another transaction happened on Sep 09 ’25, when Company’s Officer proposed sale 6,666 for $46.69, making the entire transaction worth $311,205.
Nektar Therapeutics (NKTR) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -2.25 earnings per share (EPS) during the time that was better than consensus figure (set at -2.92) by 0.67. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.06% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
You can see what Nektar Therapeutics (NKTR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.94, a number that is poised to hit -2.51 in the next quarter and is forecasted to reach -9.54 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Looking closely at Nektar Therapeutics (NASDAQ: NKTR), its last 5-days average volume was 0.7 million, which is a drop from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 51.90%.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 84.01%, which indicates a significant increase from 49.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.88 in the past 14 days, which was higher than the 3.01 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $57.18, while its 200-day Moving Average is $26.54. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $61.24. Second resistance stands at $62.89. The third major resistance level sits at $64.99. If the price goes on to break the first support level at $57.49, it is likely to go to the next support level at $55.39. Should the price break the second support level, the third support level stands at $53.74.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
There are 20,342K outstanding shares of the company, which has a market capitalization of 1.21 billion. As of now, sales total 98,430 K while income totals -118,960 K. Its latest quarter income was 11,790 K while its last quarter net income were -35,520 K.
